Reta - GLP-3
Investigational Multi-Agonist Peptide
Reta GLP-3 is a triple agonist targeting GLP-1, GIP, and glucagon receptors, being explored for its powerful metabolic effects, especially in obesity and type 2 diabetes.
Usage:
Used in clinical trials and investigational studies for significant body fat reduction, appetite control, and glucose management.
Mechanism of Action:
Acts on GLP-1, GIP, and glucagon receptors to enhance insulin sensitivity, reduce appetite, and increase energy expenditure.
Benefits:
- Substantial weight loss
- Improved glycemic control
- Enhanced metabolic rate
Side Effects:
- Nausea
- Gastrointestinal discomfort
- Possible increased heart rate
Suggested Dosage:
Not specified
Half-life: Approximately 5–7 days
Delivery: Subcutaneous injection (weekly)